CD19 and cancer: Patients receiving CD19-CAR-T had low seroconversion percentages, though most received CAR-T more than 1 year before the study, were in remission, and had not received cancer treatment in the past year, suggesting prolonged immunosuppression after CD19-CAR-T therapy.